<DOC>
	<DOCNO>NCT01043874</DOCNO>
	<brief_summary>To evaluate major molecular response ( MMR ) rate 12 month nilotinib treatment study patient Philadelphia Chromosome Positive ( Ph+ ) chronic myelogenous leukemia chronic phase ( CML-CP ) suboptimal molecular response imatinib 18 month later .</brief_summary>
	<brief_title>Study Evaluate Nilotinib Chronic Myelogenous Leukemia ( CML ) Patients With SubOptimal Response</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<criteria>1 . Male female patient ≥ 18 year age . 2 . ECOG 0 , 1 , 2 . 3 . Have diagnose Ph+ CMLCP receive imatinib therapy . 4 . Patients suboptimal molecular response imatinib treatment continue least 18 month ( first line therapy ) Suboptimal molecular response define following condition : 1 . Patients achieve CCyR ( 0 % Ph+ chromosome ) . 2 . Patients n't achieve MMR ( MMR define BCRABL/ABL ratio ≤ 0.1 % International Scale detect RQPCR ) . The treatment imatinib define : Dose 300 mg high daily must maintain minimum 3 month prior study entry . 5 . Patients meet following laboratory test criterion : 1. total bilirubin &lt; 1.5 x ULN , 2 . SGOT SGPT &lt; 2.5 x ULN , 3. creatinine &lt; 1.5 x ULN , 4 . Serum amylase lipase ≤ 1.5 x ULN , 5 . Alkaline phosphatase ≤ 2.5 x ULN unless consider tumor relate . 6 . Serum potassium , phosphorus , magnesium calcium ≥ LLN correctable supplement prior first dose study drug . 6 . Written inform consent prior study related screening procedure perform . 1 . Prior accelerate phase blast crisis CML . 2 . Previously document T315I mutation . 3 . Presence chromosomal abnormality Ph+ . 4 . Previous treatment tyrosine kinase inhibitor except imatinib . 5 . Impaired cardiac function include one following : 1 . Complete leave bundle branch block 2 . Congenital long QT syndrome family history long QT syndrome 3 . History presence significant ventricular atrial tachyarrhythmias 4 . Clinically significant rest brachycardia ( &lt; 50 bpm ) 5 . QTcF &gt; 450 msec screen ECG 6 . Use ventricularpaced pacemaker 7 . Myocardial infarction last 12 month 8 . Other clinically significant heart disease ( e.g . congestive heart failure , uncontrolled hypertension , unstable angina ) . 6 . Treatment strong CYP3A4 inducer ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentine , phenobarbital , St John 's Wort ) , treatment discontinue switched different medication prior start study drug . See Section 6.4.3 complete list medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Chronic phase</keyword>
	<keyword>Chronic myelogenous leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Philadelphia chromosome positive</keyword>
	<keyword>Ph+</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>CML-CP</keyword>
	<keyword>Suboptimal molecular response</keyword>
</DOC>